English 简体中文
产品
文章
搜索
搜索
首页 ∷ 试剂 ∷ MCE ∷ Acarbose
当前位置：
Acarbose

Acarbose

0.00
0.00
  
商品描述
Acarbose,HY-B0089 ,MCE:
Description

Acarbose is an inhibitor of alpha glucosidase, an anti-diabetic drug.

In Vitro

Acarbose (1, 2, and 3 μM) dose- and time-dependently inhibits TNF-α-induced VSMC proliferation and migration. Acarbose (1, 2, and 3 μM) dose-dependently decreases β-galactosidase, Ras expression and increased p-AMPK expression in TNF-α pre-treated A7r5 cells.

In Vivo

Acarbose (300 mg/60 kg body weight) decreases the fasting blood glucose, and regulates the glucose tolerance of DM rats without body weight loss. Acarbose significantly suppresses serum IL6 and TNF-α in DM rats. Acarbose (2.5 and 5.0 mg/kg) significantly and dose-dependently decreases the intensity of neointimal IL-6, TNF-α, and iNOS staining, and significantly increases the intensity of neointimal p-AMPK staining. Acarbose (2.5 and 5.0 mg/kg) significantly and dose-dependently decreases neointimal Ras and β-galactosidase expression in HCD-fed rabbits without body weight loss.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01863147 Wuhan General Hospital of Guangzhou Military Command Newly Diagnosed Type 2 Diabetes|Coronary Artery Disease July 2013 Phase 4
NCT01554631 Bayer Diabetes Mellitus, Type 2 March 2012 Phase 1
NCT01914133 Kenneth Madden|University of British Columbia Other Specified Hypotension|Syncope January 2014 Phase 2
NCT01728740 Bayer Diabetes Mellitus, Type II September 2012 Phase 1
NCT01490918 The Catholic University of Korea|Bayer Type-II Diabetes Mellitus April 2012 Phase 3
NCT02243176 AstraZeneca Type 2 Diabetes Mellitus September 2014 Phase 4
NCT01030952 Novartis Pharmaceuticals|Novartis Diabetes Mellitus, Type 2 December 2009 Phase 4
NCT01914133 Kenneth Madden|University of British Columbia Other Specified Hypotension|Syncope January 2014 Phase 2
NCT03383068 RenJi Hospital PCOS|Impaired Glucose Tolerance January 1, 2018 Phase 4
NCT01010100 Bayer Diabetes Mellitus August 2000 Phase 3
NCT01316861 EMS Type 2 Diabetes Mellitus September 2012 Phase 3
NCT02605772 Fifth Affiliated Hospital, Sun Yat-Sen University Type 2 Diabetes Mellitus December 2015 Phase 4
NCT00417729 Taichung Veterans General Hospital|Taipei Veterans General Hospital, Taiwan|Changhua Christian Hospital Diabetes Mellitus January 2007 Phase 4
NCT00558883 GWT-TUD GmbH|Technische Universität Dresden|Diakonissen Krankenhaus Dresden, Germany|University of Regensburg Type 2 Diabetes Mellitus|Subclinical Inflammation January 2005 Phase 3
NCT01388153 Bayer Diabetes Mellitus, Type 2 June 2011 Phase 1
NCT02589353 Oregon State University Healthy Volunteers May 1, 2016 Phase 4
NCT00909051 Bayer Diabetes Mellitus March 2009
NCT02605772 Fifth Affiliated Hospital, Sun Yat-Sen University Type 2 Diabetes Mellitus December 2015 Phase 4
NCT03344341 AstraZeneca Type 2 Diabetes Mellitus December 15, 2017 Phase 4
NCT00928889 Novartis Pharmaceuticals|Novartis Diabetes Mellitus, Type 2 July 2009 Phase 4
NCT02438397 Shanghai 6th People´s Hospital Type 2 Diabetes December 2014 Phase 4
NCT00551954 Technische Universität Dresden Type 2 Diabetes July 2006 Phase 3
NCT02953093 Montefiore Medical Center Aging November 22, 2016 Phase 2
NCT01612741 Bayer Type 2 Diabetes Mellitus April 2008
NCT00677521 The Hospital for Sick Children Non-alcoholic Fatty Liver Disease January 2007 Phase 2
NCT00558883 GWT-TUD GmbH|Technische Universität Dresden|Diakonissen Krankenhaus Dresden, Germany|University of Regensburg Type 2 Diabetes Mellitus|Subclinical Inflammation January 2005 Phase 3
NCT01863147 Wuhan General Hospital of Guangzhou Military Command Newly Diagnosed Type 2 Diabetes|Coronary Artery Disease July 2013 Phase 4
NCT02049814 Takeda Type 2 Diabetes Mellitus June 2014 Phase 4
NCT01025765 National Taiwan University Hospital|Schering-Plough|Merck Sharp & Dohme Corp. Chronic Hepatitis C November 2009 Phase 4
NCT03359837 Sanofi Type 2 Diabetes Mellitus January 20, 2018 Phase 4
NCT01470937 Indiana University School of Medicine|Bayer|Indiana University Type 2 Diabetes Mellitus February 1998 Phase 4
NCT00970528 Bayer Diabetes Mellitus, Type 2 November 2009 Phase 4
NCT01167231 Bayer Diabetes Mellitus May 2007
NCT01181674 Population Health Research Institute|Hamilton Health Sciences Corporation Type 2 Diabetes Mellitus January 2011 Phase 4
NCT02865499 The University of Texas Health Science Center at San Antonio Aging June 2016 Phase 2
NCT01758471 Shanghai Jiao Tong University School of Medicine Type 2 Diabetes December 2012 Phase 4
NCT00417729 Taichung Veterans General Hospital|Taipei Veterans General Hospital, Taiwan|Changhua Christian Hospital Diabetes Mellitus January 2007 Phase 4
NCT02879955 Hvidovre University Hospital|University of Copenhagen Overweight August 2016 Not Applicable
NCT01177384 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus January 25, 2011 Phase 3
NCT01025765 National Taiwan University Hospital|Schering-Plough|Merck Sharp & Dohme Corp. Chronic Hepatitis C November 2009 Phase 4
NCT03241303 University Hospital, Gentofte, Copenhagen|University of Copenhagen Glucose Metabolism Disorders August 1, 2017 Not Applicable
NCT01490918 The Catholic University of Korea|Bayer Type-II Diabetes Mellitus April 2012 Phase 3
NCT01624116 Services Hospital, Lahore Diabetes, Type 2 August 2011 Not Applicable
NCT01514838 Astellas Pharma Inc Type II Diabetes Mellitus April 23, 2012 Phase 3
NCT01758471 Shanghai Jiao Tong University School of Medicine Type 2 Diabetes December 2012 Phase 4
NCT01961388 Bayer Diabetes Mellitus August 2015
NCT01248481 Bayer Diabetes Mellitus September 2010
NCT01181674 Population Health Research Institute|Hamilton Health Sciences Corporation Type 2 Diabetes Mellitus January 2011 Phase 4
NCT02953093 Montefiore Medical Center Aging November 22, 2016 Phase 2
NCT01839344 Bastyr University Diabetes Mellitus, Type 2 May 2013 Phase 2
NCT00677521 The Hospital for Sick Children Non-alcoholic Fatty Liver Disease January 2007 Phase 2
NCT02211950 Boehringer Ingelheim Healthy October 2008 Phase 1
NCT01279512 Royan Institute PCO December 2006 Phase 4
NCT00846521 Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pediatric Obesity|Insulin Resistance|Impaired Glucose Tolerance|Cardiovascular Disease September 2006 Phase 4
NCT03602638 Chinese PLA General Hospital Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1 October 1, 2018 Phase 4
NCT03241303 University Hospital, Gentofte, Copenhagen|University of Copenhagen Glucose Metabolism Disorders August 1, 2017 Not Applicable
NCT01279512 Royan Institute PCO December 2006 Phase 4
NCT01613105 Bayer Type 2 Diabetes Mellitus April 2008
NCT00551954 Technische Universität Dresden Type 2 Diabetes July 2006 Phase 3
NCT01244971 Karolinska Institutet|The Swedish Research Council|Bayer Diabetes Mellitus Type 2 January 2004 Phase 4
NCT00829660 University of Oxford|Bayer Coronary Heart Disease|Acute Coronary Syndrome|Impaired Glucose Tolerance|Type 2 Diabetes Mellitus (T2DM) February 17, 2009 Phase 4
NCT01316861 EMS Type 2 Diabetes Mellitus September 2012 Phase 3
NCT00629213 GWT-TUD GmbH Metabolic Syndrome Phase 3
NCT00223691 Vanderbilt University|Vanderbilt University Medical Center Autonomic Failure|Orthostatic Hypotension March 2002 Phase 1
NCT02446834 RenJi Hospital Polycystic Ovary Syndrome April 2015 Not Applicable
NCT01612741 Bayer Type 2 Diabetes Mellitus April 2008
NCT02836704 Sanofi Diabetes Mellitus, Type 2 September 9, 2016 Phase 4
NCT00417950 Taichung Veterans General Hospital|Tri-Service General Hospital Diabetes Mellitus|Impaired Glucose Tolerance January 2007 Not Applicable
NCT00858676 Aichi Gakuin University Diabetes Mellitus|Impaired Glucose Tolerance|Coronary Artery Disease April 2009 Phase 4
NCT01019356 Jean-Patrice Baillargeon|Canadian Institutes of Health Research (CIHR)|Université de Sherbrooke Polycystic Ovary Syndrome August 2006 Not Applicable
NCT01961388 Bayer Diabetes Mellitus August 2015
NCT01198730 Taichung Veterans General Hospital Diabetes Mellitus|Coronary Artery Disease April 2009 Not Applicable
NCT00909051 Bayer Diabetes Mellitus March 2009
NCT00223691 Vanderbilt University|Vanderbilt University Medical Center Autonomic Failure|Orthostatic Hypotension March 2002 Phase 1
NCT02355509 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Glucose Intolerance|Postprandial Hyperglycemia|Cardiovascular Risk Factor January 2010 Phase 4
NCT00464594 Japan Early Diabetes Intervention Study Group Diabetes Mellitus April 2007 Not Applicable
NCT00928889 Novartis Pharmaceuticals|Novartis Diabetes Mellitus, Type 2 July 2009 Phase 4
NCT02072096 Eli Lilly and Company Diabetes Mellitus, Type 2 February 2014 Phase 4
NCT01245166 Lotus Pharmaceutical The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg|Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in|Subjects With Type 2 Diabetes Mellitus. November 2010 Phase 3
NCT02865499 The University of Texas Health Science Center at San Antonio Aging June 2016 Phase 2
NCT03380546 Assistance Publique - Hôpitaux de Paris Gestational Diabetes Mellitus in Pregnancy July 4, 2018 Phase 3
NCT01198730 Taichung Veterans General Hospital Diabetes Mellitus|Coronary Artery Disease April 2009 Not Applicable
NCT02043886 University of British Columbia|Canadian Diabetes Association Type 2 Diabetes|Postprandial Hypotension June 2007 Phase 2
NCT02438397 Shanghai 6th People´s Hospital Type 2 Diabetes December 2014 Phase 4
NCT01388153 Bayer Diabetes Mellitus, Type 2 June 2011 Phase 1
NCT00417950 Taichung Veterans General Hospital|Tri-Service General Hospital Diabetes Mellitus|Impaired Glucose Tolerance January 2007 Not Applicable
NCT02355509 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Glucose Intolerance|Postprandial Hyperglycemia|Cardiovascular Risk Factor January 2010 Phase 4
NCT00221156 Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan|Kobe City General Hospital Glucose Metabolism Disorders|Coronary Artery Disease May 2005 Phase 3
NCT00829660 University of Oxford|Bayer Coronary Heart Disease|Acute Coronary Syndrome|Impaired Glucose Tolerance|Type 2 Diabetes Mellitus (T2DM) February 17, 2009 Phase 4
NCT02143765 Zhongda Hospital Type 2 Diabetes Mellitus May 2014 Phase 4
NCT03344341 AstraZeneca Type 2 Diabetes Mellitus December 15, 2017 Phase 4
NCT03380546 Assistance Publique - Hôpitaux de Paris Gestational Diabetes Mellitus in Pregnancy July 4, 2018 Phase 3
NCT02879955 Hvidovre University Hospital|University of Copenhagen Overweight August 2016 Not Applicable
NCT02043886 University of British Columbia|Canadian Diabetes Association Type 2 Diabetes|Postprandial Hypotension June 2007 Phase 2
NCT01167231 Bayer Diabetes Mellitus May 2007
NCT01470937 Indiana University School of Medicine|Bayer|Indiana University Type 2 Diabetes Mellitus February 1998 Phase 4
NCT02211950 Boehringer Ingelheim Healthy October 2008 Phase 1
NCT02500329 Seoul National University Hospital Endothelial Function|Type 2 Diabetes|Gemigliptin|Acarbose September 2014 Phase 4
NCT00437918 Inje University|Sanofi Diabetes Mellitus|Type 2 Diabetes Mellitus January 2007 Phase 4
NCT02315495 Zilin Sun|Zhongda Hospital Type 2 Diabetes April 3, 2015 Phase 3
NCT03349684 Bayer Diabetes Mellitus, Type 2 March 5, 2018 Phase 3
NCT02315495 Zilin Sun|Zhongda Hospital Type 2 Diabetes April 3, 2015 Phase 3
NCT01244971 Karolinska Institutet|The Swedish Research Council|Bayer Diabetes Mellitus Type 2 January 2004 Phase 4
NCT02049814 Takeda Type 2 Diabetes Mellitus June 2014 Phase 4
NCT02500329 Seoul National University Hospital Endothelial Function|Type 2 Diabetes|Gemigliptin|Acarbose September 2014 Phase 4
NCT03794336 Sanofi Type 2 Diabetes Mellitus January 15, 2019 Phase 4
NCT01624116 Services Hospital, Lahore Diabetes, Type 2 August 2011 Not Applicable
NCT03794336 Sanofi Type 2 Diabetes Mellitus January 15, 2019 Phase 4
NCT02589353 Oregon State University Healthy Volunteers May 1, 2016 Phase 4
NCT01709305 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus November 8, 2012 Phase 4
NCT02243176 AstraZeneca Type 2 Diabetes Mellitus September 2014 Phase 4
NCT02446834 RenJi Hospital Polycystic Ovary Syndrome April 2015 Not Applicable
NCT02072096 Eli Lilly and Company Diabetes Mellitus, Type 2 February 2014 Phase 4
NCT01613105 Bayer Type 2 Diabetes Mellitus April 2008
NCT01030952 Novartis Pharmaceuticals|Novartis Diabetes Mellitus, Type 2 December 2009 Phase 4
NCT01010100 Bayer Diabetes Mellitus August 2000 Phase 3
NCT01175486 Taipei Veterans General Hospital, Taiwan Diabetes July 2010 Phase 4
NCT00629213 GWT-TUD GmbH Metabolic Syndrome Phase 3
NCT01514838 Astellas Pharma Inc Type II Diabetes Mellitus April 23, 2012 Phase 3
NCT01248481 Bayer Diabetes Mellitus September 2010
NCT01728740 Bayer Diabetes Mellitus, Type II September 2012 Phase 1
NCT02143765 Zhongda Hospital Type 2 Diabetes Mellitus May 2014 Phase 4
NCT03602638 Chinese PLA General Hospital Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1 October 1, 2018 Phase 4
NCT02685852 University of Minnesota - Clinical and Translational Science Institute Hyperinsulinemic Hypoglycemia February 2016 Phase 2
NCT01839344 Bastyr University Diabetes Mellitus, Type 2 May 2013 Phase 2
NCT02999841 Peking University Diabetes Mellitus, Type 2|Obesity March 2016 Phase 4
NCT01709305 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus November 8, 2012 Phase 4
NCT03359837 Sanofi Type 2 Diabetes Mellitus January 20, 2018 Phase 4
NCT00437918 Inje University|Sanofi Diabetes Mellitus|Type 2 Diabetes Mellitus January 2007 Phase 4
NCT01175486 Taipei Veterans General Hospital, Taiwan Diabetes July 2010 Phase 4
NCT01000688 Radboud University Type 2 Diabetes|Endothelial Dysfunction January 2010 Phase 3
NCT02999841 Peking University Diabetes Mellitus, Type 2|Obesity March 2016 Phase 4
NCT00858676 Aichi Gakuin University Diabetes Mellitus|Impaired Glucose Tolerance|Coronary Artery Disease April 2009 Phase 4
NCT01245166 Lotus Pharmaceutical The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg|Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in|Subjects With Type 2 Diabetes Mellitus. November 2010 Phase 3
NCT02836704 Sanofi Diabetes Mellitus, Type 2 September 9, 2016 Phase 4
NCT00846521 Yale University|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Pediatric Obesity|Insulin Resistance|Impaired Glucose Tolerance|Cardiovascular Disease September 2006 Phase 4
NCT01177384 Merck Sharp & Dohme Corp. Type 2 Diabetes Mellitus January 25, 2011 Phase 3
NCT00970528 Bayer Diabetes Mellitus, Type 2 November 2009 Phase 4
NCT01554631 Bayer Diabetes Mellitus, Type 2 March 2012 Phase 1
NCT00464594 Japan Early Diabetes Intervention Study Group Diabetes Mellitus April 2007 Not Applicable
NCT03349684 Bayer Diabetes Mellitus, Type 2 March 5, 2018 Phase 3
NCT01000688 Radboud University Type 2 Diabetes|Endothelial Dysfunction January 2010 Phase 3
NCT01019356 Jean-Patrice Baillargeon|Canadian Institutes of Health Research (CIHR)|Université de Sherbrooke Polycystic Ovary Syndrome August 2006 Not Applicable
NCT02685852 University of Minnesota - Clinical and Translational Science Institute Hyperinsulinemic Hypoglycemia February 2016 Phase 2
NCT00221156 Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan|Kobe City General Hospital Glucose Metabolism Disorders|Coronary Artery Disease May 2005 Phase 3
NCT03383068 RenJi Hospital PCOS|Impaired Glucose Tolerance January 1, 2018 Phase 4
Solvent & Solubility
In Vitro: 

H2O : 325 mg/mL (503.41 mM; Need ultrasonic)

Preparing
Stock Solutions
ConcentrationSolventMass 1 mg 5 mg 10 mg
1 mM 1.5489 mL 7.7447 mL 15.4895 mL
5 mM 0.3098 mL 1.5489 mL 3.0979 mL
10 mM 0.1549 mL 0.7745 mL 1.5489 mL
*Please refer to the solubility information to select the appropriate solvent.



相关产品：
品牌
货号
名称
规格
MCE
HY-100406-50MG
(S)-MCPG
　
MCE
HY-100421
CPI-455
5MG
MCE
HY-10071-1ml
Y-27632
1ml
MCE
HY-10071-50mg
Y-27632
50mg
MCE
HY-10108
LY294002
10 mM * 1 mL
MCE
HY-101091-5mg
Importazole
5mg
MCE
HY-101391-100mg
Picrotoxin
100mg
MCE
HY-101494-1MG
LY3214996
　
MCE
HY-10182 -1ml
CHIR-99021
1ml
MCE
HY-10219-10MG
Rapamycin
　
MCE
HY-10219-25MG
Rapamycin
　
MCE
HY-10254-1ml
PD0325901
1ml
MCE
HY-10358
MK 2206 dihydrochloride
10 mM * 1 mL
MCE
HY-10583-1ml
Y-27632 (dihydrochloride)
1ml
MCE
HY-10627A-50mg
GW3965 hydrochloride
　
MCE
HY-10627A-5MG
GW3965 hydrochloride
　
MCE
HY-108709 -1mg
CC-671
1mg
MCE
HY-10997-10MG
PCI-32765
　
MCE
HY-12028
PD98059
10 mM * 1 mL
MCE
HY-12028-5MG
PD98059
　
MCE
HY-12275
FR 180204
10 mM * 1 mL
MCE
HY-12466-1mg
Z-DEVD-FMK
1mg
MCE
HY-12526
Tetrodotoxin
1MG
MCE
HY-13315-50MG
Montelukast sodium
50MG
MCE
HY-13316
Mitomycin C
5MG
MCE
HY-13688A-10MG
PJ34
　
MCE
HY-14166-100MG
MK-886
　
MCE
HY-15310-500mg
Ivermectin
500mg
MCE
HY-15893-50mg
DMOG
50mg
MCE
HY-16563-1mg
Narciclasine
1mg
MCE
HY-17026-100mg
Gemcitabine
100mg
MCE
HY-17356-10g
Fenofibrate
　
MCE
HY-17382
Metoclopramide
100MG
MCE
HY-17538-10MG
ZLN005
10MG
MCE
HY-17561-5G
G-418 disulfate
5G
MCE
HY-17567-100mg
Heparin
100mg
MCE
HY-17567A-100mg
Heparin sodium salt
100mg
MCE
HY-17589-100MG
Chloroquine diphosphate
　
MCE
HY-18012
AVL-292
10MG
MCE
HY-19312-500MG
3-Methyladenine
　
MCE
HY-19312-50mg
3-Methyladenine
50mg
MCE
HY-19538-1mg
FRAX1036
1mg
MCE
HY-50846-2MG
SCH772984
　
MCE
HY-50907-1ml
ABT-737
1ml
MCE
HY-66009-1ml
Epalrestat
1ml
MCE
HY-B0089
Acarbose
200MG
MCE
HY-B0141-1G
Estradiol
1g
MCE
HY-B0795-5MG
MHY1485
　
MCE
HY-B0919-1ml
Azaserine
1ml
MCE
HY-B1041-1ml
Aminoguanidine hydrochloride
1ml
MCE
HY-B1743A
Puromycin dihydrochloride
10 mM * 1 mL
MCE
HY-B1756-5g
Rotenone
5g
MCE
HY-N0219
(+)-Bicuculline
100MG
MCE
HY-N0390-100mg
L-Glutamine
100mg
MCE
HY-N0583 -1G
Hydrocortisone
1g
MCE
HY-P0035-10mg
Insulin(human)
10mg
MCE
HY-P7011-10ug
Recombinant Human Epiregulin
10ug
MCE
HY-P7154-10ug
Recombinant Mouse DKK-1 (CHO-expressed)
10ug